Journal of Clinical Immunology

, Volume 23, Issue 6, pp 439–446

Fas Ligand-Mediated Apoptosis in Degenerative Disorders of the Brain

Article

DOI: 10.1023/B:JOCI.0000010420.96419.a8

Cite this article as:
Ethell, D.W. & Buhler, L.A. J Clin Immunol (2003) 23: 439. doi:10.1023/B:JOCI.0000010420.96419.a8

Abstract

While defective apoptosis predisposes to neoplasia, inappropriate apoptosis in the brain leads to permanent neurological deficits. Disregulated apoptosis has been implicated in several neurodegenerative disorders including Alzheimer's, Parkinson's, and Huntington's diseases. Recent reports have suggested that the key apoptosis regulator Fas ligand (FasL) may participate in both neuronal and immune cell apoptosis in Alzheimer's disease. FasL has also been implicated as a negative regulator for the inflammatory component of the demyelinating brain disorder multiple sclerosis (MS). Here we discuss how FasL-mediated apoptosis may balance immune cell access to the brain with Alzheimer's disease and MS representing extremes of too little and too much immune access, respectively.

Alzheimer's apoptosis EAE FasL multiple sclerosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Plenum Publishing Corporation 2003

Authors and Affiliations

  1. 1.Division of Biomedical SciencesUniversity of California RiversideRiverside
  2. 2.Graduate program in Biochemistry and Molecular BiologyUSA

Personalised recommendations